New hope for kids with tough cancers: drug combo trial launches
NCT ID NCT07444918
First seen Mar 07, 2026 · Last updated Apr 29, 2026 · Updated 10 times
Summary
This study tests a mix of chemotherapy drugs (liposomal irinotecan, vincristine, temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have come back or not responded to treatment. The goal is to see if the combination can shrink tumors and control the disease, while monitoring side effects. About 33 participants will receive treatment in 21-day cycles, with doses adjusted based on their condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PEDIATRIC MALIGNANT SOLID TUMORS (INCLUDING NEUROBLASTOMA, RHABDOMYOSARCOMA, EWING SARCOMA, OSTEOSARCOMA) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.